While the applicability of the Antibody Discovery Engine is broad, Immunome’s internal focus is on the development of new therapies for oncology and infectious diseases.

Our platform produces unique insights into the biology of cancer – uncovering a compelling picture as multiple non-canonical targets have accrued from our efforts. While there is often little information available on unique antigens, our data reveals a “functional clustering” of the targets to which cancer patients were mounting an immune response. In essence, these findings reveal the key methods by which each patient’s immune system fights back against their disease. These functional clusters may provide an important insight into the most important tumor-driven processes that should be attacked to overcome a disease threat.

Our platform is also being leveraged in the fight against COVID-19. The Antibody Discovery Engine is being used to interrogate the immune response of COVID-19 “super-responders”, individuals who have successfully fought the virus. We aim to isolate antibodies against multiple viral clearance mechanisms and use a mixture of them to develop a Biosynthetic Convalescent Plasma (BCP) that can be of potential use in both treatment and prophylactic settings. We are currently engaged in the research and development of the optimum antibody mixture.